Abstract
Oral squamous cell carcinoma (OSCC) is an epithelial malignant tumor with great challenges of tumor metastasis and drug resistance. Nutlin-3 is a MDM2 inhibitor that can potently activate tumor suppressor gene p53. However, the exact role of Nutlin-3 in OSCC has not been identified yet. SCC-9 cells were treated with 0, 2.5, 5, 10, 20 μM Nutlin3. MDM2 and p53 protein levels were assessed using western blot analysis. Then, CCK8 assay, clone formation assay, TUNEL staining, wound healing and transwell assays were conducted to analyze the influences of Nutlin3 on the proliferation, apoptosis, migration, and invasion in SCC-9 cells. Moreover, SCC-9 cells were co-treated with 0, 0.5, 1, 2.5, 5 μM cisplatin and Nutlin3 to determine the effect of Nutlin3 on cisplatin chemosensitivity in OSCC. As expected, Nutlin-3 inhibited MDM2 but restored p53 in OSCC in a concentration-dependent manner. Meanwhile, Nutlin-3 suppressed the proliferation, clone formation, migration, invasion and epithelial-mesenchymal transition of SCC-9 cells and both boosted the apoptosis. In addition, Nutlin-3 caused a reduced cell viability and an elevated cell apoptosis rate in cisplatin-treated SCC-9 cells, indicating that Nutlin-3 enhanced cisplatin chemosensitivity in OSCC cells. Taken together, Nutlin-3 may suppress tumorigenesis and progression of OSCC and enhance chemosensitivity to cisplatin in OSCC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.
References
Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA (2009) Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 119:1438–1449. https://doi.org/10.1172/JCI38019
Best SA, Vandenberg CJ, Abad E, Whitehead L, Guiu L, Ding S, Brennan MS, Strasser A, Herold MJ, Sutherland KD, Janic A (2020) Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis. Cell Death Dis 11:877. https://doi.org/10.1038/s41419-020-03066-9
Biddle A, Gammon L, Liang X, Costea DE, Mackenzie IC (2016) Phenotypic plasticity determines cancer stem cell therapeutic resistance in oral squamous cell carcinoma. EBioMedicine 4:138–145. https://doi.org/10.1016/j.ebiom.2016.01.007
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Bulsara VM, Worthington HV, Glenny AM, Clarkson JE, Conway DI, Macluskey M (2018) Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev 12:CD006205. https://doi.org/10.1002/14651858.CD006205.pub4
Chen F, Cao Y, Huang J, Yan L, Lin L, Liu F, Liu F, Wu J, Qiu Y, Cai L, He B (2017) A novel prognostic index for oral squamous cell carcinoma patients with surgically treated. Oncotarget 8:55525–55533
Chipuk JE, Maurer U, Green DR, Schuler M (2003) Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4:371–381. https://doi.org/10.1016/s1535-6108(03)00272-1
Feng J, Xu J, Xu Y, Xiong J, Xiao T, Jiang C, Li X, Wang Q, Li J, Li Y (2019) CLIC1 promotes the progression of oral squamous cell carcinoma via integrins/ERK pathways. Am J Transl Res 11:557–571
Fernandes-Alnemri T, Litwack G, Alnemri ES (1994) CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269:30761–30764
Hainaut P, Milner J (1993) A structural role for metal ions in the “wild-type” conformation of the tumor suppressor protein p53. Cancer Res 53:1739–1742
Hou H, Sun D, Zhang X (2019) The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int 19:216. https://doi.org/10.1186/s12935-019-0937-4
Huang Z, Zhang Q, Wang Y, Chen R, Wang Y, Huang Z, Zhou G, Li H, Rui X, Jin T, Li S, Zhang Y, Huang Z (2020) Inhibition of caspase-3-mediated GSDME-derived pyroptosis aids in noncancerous tissue protection of squamous cell carcinoma patients during cisplatin-based chemotherapy. Am J Cancer Res 10:4287–4307
Kastenhuber ER, Lowe SW (2017) Putting p53 in context. Cell 170:1062–1078. https://doi.org/10.1016/j.cell.2017.08.028
Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948–953. https://doi.org/10.1126/science.274.5289.948
Liu X, Cao Y, Zhang Y, Zhou H, Li H (2019) Regulatory effect of MiR103 on proliferation, EMT and invasion of oral squamous carcinoma cell through SALL4. Eur Rev Med Pharmacol Sci 23:9931–9938
Major AG, Pitty LP, Farah CS (2013) Cancer stem cell markers in head and neck squamous cell carcinoma. Stem Cells Int 2013:319489. https://doi.org/10.1155/2013/319489
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37–43. https://doi.org/10.1038/376037a0
Ouyang Y, Jiang F, Zeng B, Wei C, Yu D (2017) miR-222 knockdown suppresses epithelial-to-mesenchymal transitionin human oral squamous cell carcinoma. Int J Clin Exp Pathol 10:11251–11259
Thomson PJ (2018) Perspectives on oral squamous cell carcinoma prevention-proliferation, position, progression and prediction. J Oral Pathol Med 47:803–807. https://doi.org/10.1111/jop.12733
Voon YL, Ahmad M, Wong PF, Husaini R, Ng WT, Leong CO, Lane DP, Khoo AS (2015) Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity. Oncol Rep 34:1692–1700. https://doi.org/10.3892/or.2015.4177
Wang R, Lu X, Yu R (2020) lncRNA MALAT1 promotes EMT process and cisplatin resistance of oral squamous cell carcinoma via PI3K/AKT/m-TOR signal pathway. Onco Targets Ther 13:4049–4061. https://doi.org/10.2147/OTT.S251518
Yan L, Chen F, Liu F, Qiu Y, Wang J, Wu J, Bao X, Hu Z, Peng X, Lin X, Cai L, Lin L, He B (2017) Differences in modifiable factors of oral squamous cell carcinoma in the upper and lower of oral fissure. Oncotarget 8:75094–75101
Yao Y, Zhou WY, He RX (2019) Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-κB pathway. Biomed Pharmacother 109:1994–2004. https://doi.org/10.1016/j.biopha.2018.07.144
Zeisberg M, Neilson EG (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119:1429–1437. https://doi.org/10.1172/JCI36183
Zhao Y, Yu H, Hu W (2014) The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin (shanghai) 46:180–189. https://doi.org/10.1093/abbs/gmt147
Zheng T, Yin D, Lu Z, Wang J, Li Y, Chen X, Liang Y, Song X, Qi S, Sun B, Xie C, Meng X, Pan S, Liu J, Jiang H, Liu L (2014) Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma. Mol Cancer 13:133. https://doi.org/10.1186/1476-4598-13-133
Zhu Y, Regunath K, Jacq X, Prives C (2013) Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry. Genes Dev 27:1739–1751. https://doi.org/10.1101/gad.212258.112
Acknowledgements
Not applicable.
Funding
A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, 2018-87).
Author information
Authors and Affiliations
Contributions
KZ, ZL, XD and HL designed the study, performed the experiments, analyzed the data, wrote the manuscript and revised the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
No competing interest exists in this manuscript.
Ethical approval
Not applicable. This study only contains in vitro experiments.
Consent for publication
All authors approve to submit the manuscript to your journal for publication.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zheng, K., Li, Z., Ding, X. et al. Nutlin-3 suppresses tumorigenesis and progression of oral squamous cell carcinoma and enhances chemosensitivity to cisplatin. Cytotechnology 75, 17–25 (2023). https://doi.org/10.1007/s10616-022-00556-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-022-00556-w